Physician profile
Barbara Kage
NPI 1427043538
$21,389.24
in general payments reported to CMS, 2019-2025
42 companies · $2,795 in 2025
The $2,795 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $844 · 2021: $1,179 · 2022: $1,716 · 2023: $8,528 · 2024: $5,370 · 2025: $2,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,636 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Consulting Fee: $750 · Education: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,635.76 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Consulting Fee | $750.00 |
| Education | $557.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,414.43 | 2020-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $2,498.25 | 2019-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $1,558.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,130.84 | 2019-2025 | |
| Ucb, INC. | $1,117.38 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $1,073.94 | 2020-2025 | Acthar |
| Lilly USA, LLC | $787.14 | 2019-2025 | Taltz, Zepbound, Omvoh |
| Astrazeneca Pharmaceuticals LP | $503.14 | 2021-2025 | Saphnelo |
| Pfizer INC. | $354.16 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $302.82 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $295.44 | 2019-2025 | Orencia |
| Genentech USA, INC. | $282.85 | 2019-2025 | Actemra, Gazyva |
| Regeneron Healthcare Solutions, INC. | $274.05 | 2019-2025 | Dupixent |
| Horizon Therapeutics Plc | $250.13 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $241.95 | 2019-2025 | Benlysta, Nucala |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Kage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.